Loading…
Employees: 231
Size Capricor Therapeutics (CAPR) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $523M, the 2658th largest of 3,117 United States companies the cockpit tracks. Shares closed at $9.00 on 6 Nov 2026.
Performance Over six months the shares fell 73.5%, against -16.1% for the median peer and -1.1% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +9.8%).
Capital Return on invested capital runs 115.8 points below its cost of capital (8.3% WACC).
Short interest Short interest is 34.2% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $22.3M | $25.2M | $2.55M |
| Revenue growth | — | -100% | -12% | +887% | — |
| Gross profit | -$2.09M | -$1.89M | $20.8M | $24.1M | $1.86M |
| EBITDA | -$133M | -$106M | -$41.1M | -$23.0M | -$29.0M |
| Net income | -$129M | -$105M | -$40.5M | -$22.3M | -$29.0M |
| Free cash flow | -$130M | -$81.5M | -$41.5M | -$27.6M | $1.56M |
| Capital expenditure | $25.8M | $11.7M | $1.54M | $2.05M | $3.36M |
| Total debt | $91.0M | $17.9M | $4.83M | $5.61M | $5.94M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CAPR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +12.4% | -9.3% | 4th highest of 21 |
| 6-month return | -73.5% | -16.1% | lowest of 21 |
| Distance from 52-week high | -77.7% | -34.1% | lowest of 21 |
| Revenue growth (TTM) | -100.0% | +9.8% | 2nd lowest of 20 |
| ROIC minus cost of capital | -115.8 pp | -2.6 pp | 2nd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Capricor Therapeutics CAPR | United States | $523M | -73% | -100% | n/a | n/a | n/a | n/a |
| Newland Pharmaceutical 301277.SZ | China | $523M | -22% | +9% | 11% | 3.9× | 10.2% | +9.1% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $524M | -5% | +18% | 39% | 28.5× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $525M | +43% | +68% | 37% | 11.3× | 12.9% | +126.7% |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $520M | -20% | -1% | 10% | 2.1× | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $528M | +67% | +39% | -604% | 73.5× | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $519M | -18% | -4% | 18% | 4.0× | 6.7% | -4.1% |
| Morepen Laboratories MOREPENLAB.NS | India | $529M | +110% | +30% | 11% | 2.2× | n/a | n/a |
| Boryung 003850.KS | South Korea | $531M | -14% | +6% | 6% | 0.7× | -8.9% | +12.6% |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $514M | -32% | -4% | -11% | 9.8× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $533M | -5% | -5% | 7% | 2.7× | 17.7% | +4.4% |
| ChengDa PharmaCeuticals 301201.SZ | China | $535M | -43% | +27% | -9% | 5.7× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $510M | +64% | n/a | n/a | n/a | n/a | n/a |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $538M | -22% | -8% | 16% | 2.4× | -5.2% | +9.6% |
| Zeria Pharmaceutical 4559.T | Japan | $540M | -6% | +12% | 15% | 1.0× | -12.5% | +11.1% |
| Gyre Therapeutics GYRE | United States | $505M | -36% | +17% | -11% | 4.1× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $544M | -14% | +10% | 39% | 5.3× | -3.9% | +7.6% |
| REGENXBIO RGNX | United States | $503M | -28% | +12% | -94% | 3.7× | n/a | n/a |
| Xiangxue Pharmaceutical 300147.SZ | China | $502M | -49% | +3% | -39% | 3.3× | 47.1% | -12.3% |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $546M | -44% | +14% | 0% | 1.9× | n/a | n/a |
| Entera Bio ENTX | United States | $546M | +142% | -100% | n/a | n/a | n/a | n/a |